Integra Lifesciences (NASDAQ:IART) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you’ll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.88, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 6.86% decline, the current average is now lower than the previous average price target o…